Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase
Authors:
- 10 February 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (3) , 410-421
Abstract
Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases. To aid in the discovery and development of BTK inhibitors and improve clinical diagnoses, we have developed a positron emission tomography (PET) radiotracer based on a selective BTK inhibitor, remibrutinib. [18F]PTBTK3 is an aromatic, 18F-labeled tracer that was synthesized in 3 steps with a 14.8 +/- 2.4% decay-corrected radiochemical yield and >= 99% radiochemical purity. The cellular uptake of [18F]PTBTK3 was blocked up to 97% in JeKo-1 cells using remibrutinib or non-radioactive PTBTK3. [18F]PTBTK3 exhibited renal and hepatobiliary clearance in NOD SCID (non obese diabetic/severe combined immunodeficiency) mice, and the tumor uptake of [18F]PTBTK3 in BTK-positive JeKo-1 xenografts (1.23 +/- 0.30% ID/cc) was significantly greater at 60 min post injection compared to the tumor uptake in BTK-negative U87MG xenografts (0.41 +/- 0.11% ID/cc). In the JeKo-1 xenografts, tumor uptake was blocked up to 62% by remibrutinib, indicating the BTK-dependent uptake of [18F]PTBTK3 in tumors.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (EB024549, EB029860)
- Stony Brook University (T32GM127253)
This publication has 42 references indexed in Scilit:
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingMolecules, 2015
- Non-invasive PET Imaging of PARP1 Expression in Glioblastoma ModelsMolecular Imaging and Biology, 2015
- Translating slow-binding inhibition kinetics into cellular and in vivo effectsNature Chemical Biology, 2015
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Ibrutinib and novel BTK inhibitors in clinical developmentJournal of Hematology & Oncology, 2013
- Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγBlood, 2011
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences, 2007
- Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomographyJournal of Fluorine Chemistry, 2006
- Clinical utility of FDG PETThe Journal of Medical Investigation, 2004